Organon (OGN) Enterprise Value (2020 - 2026)
Organon (OGN) recorded quarterly Enterprise Value of -$1.1 billion in Q1 2026, down 94.43% quarter-over-quarter from -$574.0 million in Q4 2025, and down 104.02% on a YoY basis from $27.7 billion in Q1 2025.
Organon (OGN) Enterprise Value (2020 - 2026) Analysis & Trends
Organon's Enterprise Value history runs 7 years deep, the most recent figure standing at -$1.1 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 104.02% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 104.02% YoY), while the FY2025 annual figure was -$574.0 million, up 18.47% from the prior year.
- Enterprise Value was -$1.1 billion for Q1 2026 at Organon, down from -$574.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$326.0 million in Q2 2023 to a low of -$1.1 billion in Q1 2026.
- Historically, Enterprise Value has averaged -$623.5 million across 5 years, with a median of -$599.0 million in 2025.
- Biggest YoY gain for Enterprise Value was 50.5% in 2022; the steepest drop was 392.2% in 2022.
- A 5-year view of Enterprise Value shows it stood at -$706.0 million in 2022, then rose by 0.57% to -$702.0 million in 2023, then retreated by 0.28% to -$704.0 million in 2024, then gained by 18.47% to -$574.0 million in 2025, then slumped by 94.43% to -$1.1 billion in 2026.
- The last three Enterprise Value figures came in at -$1.1 billion (Q1 2026), -$574.0 million (Q4 2025), and -$672.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | -1.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.12 Bn |
| Dec 31, 2025 | -574.00 Mn |
| Sep 30, 2025 | -672.00 Mn |
| Jun 30, 2025 | -599.00 Mn |
| Mar 31, 2025 | -547.00 Mn |
| Dec 31, 2024 | -704.00 Mn |
| Sep 30, 2024 | -763.00 Mn |
| Jun 30, 2024 | -704.00 Mn |
| Mar 31, 2024 | -575.00 Mn |
| Dec 31, 2023 | -702.00 Mn |
| Sep 30, 2023 | -414.00 Mn |
| Jun 30, 2023 | -326.00 Mn |
| Mar 31, 2023 | -459.00 Mn |
| Dec 31, 2022 | -706.00 Mn |
| Sep 30, 2022 | -499.00 Mn |
| Jun 30, 2022 | -545.00 Mn |
| Mar 31, 2022 | -694.00 Mn |
| Dec 31, 2021 | -737.00 Mn |
| Sep 30, 2021 | -1.01 Bn |
| Jun 30, 2021 | -730.00 Mn |